The takeaway
MoonLake Immunotherapeutics shows a pronounced seasonal pattern over 6 years of data — strongest in June (+15.7%) and softest in February (+7.4%).
Right now
In July, the stock has risen 60% of years, averaging +9.0%, about +6.9 pts better than the S&P 500.
The full picture
MoonLake Immunotherapeutics's most dependable month has been June, higher in 4 of 5 years; February has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in June (+15.4 pts); it has trailed the market most in September (−15.8 pts).
“vs S&P” is MoonLake Immunotherapeutics’s average for a month minus the S&P 500’s average for that same month — isolating MoonLake Immunotherapeutics’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, June has closed higher 80% of the time versus 80% across the last 6 years — the pattern is holding.
Figures are the typical (median) June return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Dependability is the through-line here. June stands out, higher in 4 of 5 Junes, but it heads a clutch of months that pull the year reliably upward.
The headline flatters a touch — its +15.7% average sits well above the +4.7% a typical year delivers, the work of a few big Junes. That reliability comes with real swings, mind — even June ranges by 37.9% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: June has cleared the S&P 500 by +15.4 points above the index. That consistency sets it apart from the field, where the average stock manages June only about 52% of the time.
The strength clusters rather than stands alone — June–September forms a firm stretch that carries much of the year. At the other end of the calendar, February is the year's low point, though even there the stock has stayed positive on average (+7.4%), a sign every month leans up, and the edge isn't year-round — the stock has trailed the S&P 500 in September, April, and January. Its roughest month on record was a −87.8% September in 2025 — a reminder of how hard even a seasonal name can fall.
The takeaway is less about when to buy than what to expect: June aside, the stock's months offer little reliable tilt. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (June), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (June, +15.7%) has run well ahead of its worst (February, +7.4%) — the heatmap above shows how steady that gap has been year to year.
June has been the strongest, averaging +15.7% and closing higher in 4 of 5 years since 2020.
It's the weakest month, but it has still averaged a small gain (+7.4%) — quiet rather than genuinely bad.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade